{
    "clinical_study": {
        "@rank": "45266", 
        "arm_group": [
            {
                "arm_group_label": "Oseltamivir Combining HD-DXM", 
                "arm_group_type": "Active Comparator", 
                "description": "Oseltamivir 75mg twice per day, 5 consecutive days Dexamethasone 40mg per day, 4 consecutive days"
            }, 
            {
                "arm_group_label": "HD-DXM", 
                "arm_group_type": "Active Comparator", 
                "description": "Dexamethasone 40 mg per day, 4 consecutive days"
            }
        ], 
        "brief_summary": {
            "textblock": "Oseltamivirphosphate is hydrolysed to its active metabolite-the free carboxylate of\n      oseltamivir. Oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor of\n      the activity of the viral neuraminidase (NA) enzyme upon sialic acid, found on glycoproteins\n      on the surface of platelets. By blocking the activity of the enzyme, oseltamivir may prevent\n      platelet destruction in liver.The project was undertaking by Qilu Hospital of Shandong\n      University and other 5 well-known hospitals in China. In order to report the efficacy and\n      safety of oseltamivirphosphate combined with high-dose dexamethasone for the treatment of\n      immune thrombocytopenia (ITP) with high platelet desialylation level, compared to high-dose\n      dexamethasone therapy."
        }, 
        "brief_title": "A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level", 
        "condition": "Focus of Study", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "The investigators are undertaking a parallel group, multicentre, randomised controlled trial\n      of 240 newly diagnosed ITP adult patients with high platelet desialylation level from 6\n      medical centers in China. One part of the participants are randomly selected to receive\n      oseltamivirphosphate (oral administration at a dose of 75 mg twice for 5 consecutive days),\n      combining with dexamethasone (given intravenously at a dose of 40 mg per day for 4 days, the\n      others are selected to receive high-dose of dexamethasone treatment (given intravenously at\n      a dose of 40 mg daily for 4 days).\n\n      Platelet count, bleeding and other symptoms were evaluated before and after treatment.\n      Adverse events are also recorded throughout the study. In order to report the efficacy and\n      safety of oseltamivirphosphate combining with high-dose dexamethasone therapy compared to\n      high-dose dexamethasone for the treatment of adults with newly diagnosed ITP with high\n      platelet desialylation level."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  newly diagnosed ITP patients with high platelet desialylation level need of\n             treatment(s) to minimize the risk of clinically significant bleeding primary ITP\n             confirmed by excluding other supervened causes of thrombocytopenia\n\n        Exclusion Criteria:\n\n          -  pregnancy hypertension cardiovascular disease diabetes liver and kidney function\n             impairment HCV, HIV, HBsAg seropositive status patients with systemic lupus\n             erythematosus and/or antiphospholipid syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965626", 
            "org_study_id": "ITP-Oseltamivir", 
            "secondary_id": "ITP-Oseltamivirphosphate"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oseltamivir Combining HD-DXM", 
                "description": "Oseltamivir 75 mg twice per day, 5 consecutive days", 
                "intervention_name": "Oseltamivir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Oseltamivir Combining HD-DXM", 
                    "HD-DXM"
                ], 
                "description": "Dexamethasone 40 mg per day, 4 consecutive days", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101", 
                "Oseltamivir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Oseltamivir", 
            "Dexamethasone", 
            "ITP"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "contact": {
                "email": "houming@medmail.com.cn", 
                "last_name": "Ming Hou"
            }, 
            "facility": {
                "address": {
                    "city": "Jinan", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "250012"
                }, 
                "name": "Qilu hospital, Shandong University"
            }, 
            "investigator": {
                "last_name": "Ming Hou", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level", 
        "overall_contact": {
            "email": "houming@medmail.com.cn", 
            "last_name": "Ming Hou, Docter"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "People's Republic of China: National Health and Family Planning Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "R. A response (R) was defined as a sustained (\u2265 3 months) platelet count \u2265 30\u00d710^9/L without recurrence of thrombocytopenia", 
            "measure": "Evaluation of platelet response", 
            "safety_issue": "Yes", 
            "time_frame": "Newly diagnosed ITP in 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965626"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong University", 
            "investigator_full_name": "Ming Hou", 
            "investigator_title": "Professor and Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": [
            {
                "PMID": "19846889", 
                "citation": "Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. Epub 2009 Oct 21. Review."
            }, 
            {
                "PMID": "19005182", 
                "citation": "Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, K\u00fchne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. Epub 2008 Nov 12."
            }
        ], 
        "source": "Shandong University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Anhui Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The First Affiliated Hospital of Dalian Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shenzhen Second People's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Traditional Medicine Hospital of Zhejiang Province", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Shandong University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}